PRIMARY STUDY

Cannabidiol for the treatment of psychosis in Parkinson's disease

Key Findings:  In this open-label pilot study 6 outpatients diagnosed with PD and psychotic episodes for at least 3 months received CBD as a flexible dose (starting with an oral dose of 150 mg/day) for 4 weeks in addition to their pharmaceutical regime. Data revealed a significant reduction in psychotic symptoms a decrease in the total scores of the Unified Parkinson's Disease Rating Scale. No adverse effect were observed. The authors posit that CBD may be effective and safe treatment in this particular patient population.

Type of Study:  Human Trial

Study Sample Size:  6

Study Result:  Positive


Cannabinoids Studied:  Cannabidiol (CBD)

Phytocannabinoid Source:  Unspecified

Chemotype:  Chemotype III

Form of Administration:  Ingestion


Study Location(s):  Brazil

Year of Pub:  2009


Link to study